PRESS RELEASE published on 03/25/2025 at 07:30, 8 months 11 days ago CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program CROSSJECT enhances collaboration with ETON PHARMACEUTICALS Inc. on ZENEO adrenal insufficiency program, introducing new hydrocortisone formulation for the hospital market Eton Pharmaceuticals Crossject Hydrocortisone Adrenal Insufficiency ZENEO
BRIEF published on 03/10/2025 at 14:22, 8 months 26 days ago Crossject : Mise à jour sur les droits de vote et actions au 31 janvier 2025 Droits De Vote Capital Social Actions Pharmaceutique Crossject
BRIEF published on 03/10/2025 at 14:22, 8 months 26 days ago Crossject: Update on voting rights and shares as of January 31, 2025 Share Capital Voting Rights Actions Pharmaceutical Crossject
PRESS RELEASE published on 03/10/2025 at 14:17, 8 months 26 days ago Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social Crossject communique le nombre total de droits de vote et d’actions composant son capital social au 31 janvier 2025, conformément aux règlements de l’AMF et du Code de commerce Droits De Vote Capital Social Pharmaceutique Communiqué Crossject
BRIEF published on 02/12/2025 at 07:35, 9 months 21 days ago Crossject Reappoints Key Members to Executive Board Executive Board Crossject ZEPIZURE® Reappointment Needle-free Technology
BRIEF published on 02/12/2025 at 07:35, 9 months 21 days ago Crossject renouvelle le mandat de membres clés de son conseil d'administration Conseil Exécutif Crossject ZEPIZURE® Renouvellement De Nomination Technologie Sans Aiguille
PRESS RELEASE published on 02/12/2025 at 07:30, 9 months 21 days ago Crossject announces the reappointment of Patrick Alexandre and Isabelle Liebschutz as members of new, streamlined Executive Board Crossject reappoints Patrick Alexandre and Isabelle Liebschutz to its Executive Board, focusing on final stages of ZEPIZURE registration with the FDA Executive Board Crossject Patrick Alexandre Isabelle Liebschutz ZEPIZURE Registration
PRESS RELEASE published on 02/12/2025 at 07:30, 9 months 21 days ago Crossject annonce le renouvellement de Patrick Alexandre et Isabelle Liebschutz dans leurs fonctions de membres d’un nouveau Directoire ressérré Crossject renouvelle Patrick Alexandre et Isabelle Liebschutz au sein d'un nouveau Directoire resserré pour se concentrer sur l'enregistrement du ZEPIZURE® auprès de la FDA et la commercialisation aux Etats-Unis FDA Renouvellement Crossject ZEPIZURE® Directoire
BRIEF published on 02/06/2025 at 07:35, 9 months 27 days ago Modification des Obligations Convertibles par Crossject Financement Obligations Convertibles Crossject ZEPIZURE Heights Capital
BRIEF published on 02/06/2025 at 07:35, 9 months 27 days ago Modification of Convertible Bonds by Crossject Convertible Bonds Funding Crossject ZEPIZURE Heights Capital
Published on 12/05/2025 at 19:20, 24 minutes ago The Multi-Sector Validation Shock: Why SMX Became Impossible for Markets to Ignore
Published on 12/05/2025 at 18:45, 59 minutes ago Four Global Markets, One Engine: SMX Just Redefined What a Supply Chain Can Prove
Published on 12/05/2025 at 18:20, 1 hour 24 minutes ago NuRAN Announces Intention to Complete Consolidation in Preparation to the Restructuring Transaction
Published on 12/05/2025 at 18:00, 1 hour 44 minutes ago SMX: A New Supply Chain Reality in the World's Four Largest Markets
Published on 12/05/2025 at 17:15, 2 hours 29 minutes ago TRX GOLD Attending the 3rd Annual DealFlow Discovery Conference
Published on 12/05/2025 at 18:58, 46 minutes ago EQS-Adhoc: HORNBACH Holding AG & Co. KGaA: Reduced earnings in Q3 2025/26 – Guidance for adjusted EBIT at previous year’s level still valid
Published on 12/05/2025 at 18:15, 1 hour 28 minutes ago Completion of merger to form Helvetia Baloise Holding Ltd
Published on 12/05/2025 at 17:46, 1 hour 58 minutes ago Booster Precision Components Holding GmbH announces the successful completion of its Written Procedure to amend and waive certain terms under the terms and conditions of the Bonds
Published on 12/05/2025 at 17:18, 2 hours 26 minutes ago La vidéo de la réunion de présentation des résultats 2024-2025 du 5 décembre 2025 est disponible
Published on 12/05/2025 at 17:18, 2 hours 26 minutes ago The video of the 2024-2025 results presentation meeting on December 5, 2025, is available
Published on 12/05/2025 at 15:10, 4 hours 33 minutes ago Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 15:10, 4 hours 33 minutes ago Mersen : nombre d'actions et de droits de vote au 30 novembre 2025
Published on 12/05/2025 at 13:58, 5 hours 45 minutes ago RELATIF A LA MISE A DISPOSITION DU PUBLIC DE LA NOTE D'INFORMATION ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES, NOTAMMENT JURIDIQUES, FINANCIERES ET COMPTABLES DE LEGRAND FRANCE